๊ฒฝ๋ จ์„ฑ ๋‡Œ์ „์ฆ์ง€์†์ƒํƒœ ์น˜๋ฃŒ / Convulsive status epilepticus treatment

์ •์˜

Convulsive status epilepticus๋Š” ์ „์‹  ๊ฒฝ๋ จ์ด ์ง€์†๋˜๋Š” ์‘๊ธ‰ ์‹ ๊ฒฝํ•™์  ์ƒํƒœ๋กœ, raw ์ž๋ฃŒ์—์„œ๋Š” actively convulsing ์ƒํƒœ๊ฐ€ 5๋ถ„์„ ๋„˜์œผ๋ฉด ์น˜๋ฃŒ๋ฅผ ์‹œ์ž‘ํ•˜๋Š” ๊ธฐ์ค€์œผ๋กœ ์ œ์‹œ๋˜์—ˆ๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

์น˜๋ฃŒ ์ง€์—ฐ์€ ์˜ˆํ›„๋ฅผ ์•…ํ™”์‹œํ‚ฌ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ 5๋ถ„ ์ด์ƒ ์ง€์†๋˜๋Š” ๊ฒฝ๋ จ์€ ์ฆ‰์‹œ ์•ฝ๋ฌผ ์น˜๋ฃŒ์™€ ๊ธฐ๋„ ์ค€๋น„๋ฅผ ๋ณ‘ํ–‰ํ•œ๋‹ค. 1์ฐจ๋Š” benzodiazepine์ด๋ฉฐ, lorazepam IV๊ฐ€ ๋Œ€ํ‘œ์ ์ด๋‹ค. BZD ํ›„์—๋„ ์ง€์† ๋˜๋Š” ์žฌ๋ฐœํ•˜๋ฉด 2์ฐจ ํ•ญ๊ฒฝ๋ จ์ œ loading์œผ๋กœ ๋„˜์–ด๊ฐ„๋‹ค. ํ˜ธํก ์–ต์ œ ๊ฐ€๋Šฅ์„ฑ ๋•Œ๋ฌธ์— airway/respiration monitoring, BVM, intubation ์ค€๋น„๊ฐ€ ํ•„์š”ํ•˜๋‹ค.

์ง„๋‹จ

์ž„์ƒ์ ์œผ๋กœ ์ง€์†์ ์ธ ์ „์‹  ๊ฐ•์ง๊ฐ„๋Œ€ ๊ฒฝ๋ จ์ด 5๋ถ„ ์ด์ƒ์ด๋ฉด convulsive status epilepticus๋กœ ๋ณด๊ณ  ์น˜๋ฃŒํ•œ๋‹ค. ์น˜๋ฃŒ ๋ฐ˜์‘ ์—ฌ๋ถ€์— ๋”ฐ๋ผ benzodiazepine-responsive, benzodiazepine-refractory, refractory pathway๋กœ ๊ตฌ๋ถ„ํ•ด ์ ‘๊ทผํ•œ๋‹ค.

์น˜๋ฃŒ

  1. actively convulsing >5๋ถ„: lorazepam 4 mg IV slow ๋˜๋Š” ์•ฝ 0.1 mg/kg IV, ์ตœ๋Œ€ 4 mg/dose.
  2. ์ง€์†/์žฌ๋ฐœ ์‹œ 10โ€“15๋ถ„ ๊ด€์ฐฐ ํ›„ lorazepam 4 mg IV 1ํšŒ ์ถ”๊ฐ€ ๊ฐ€๋Šฅ.
  3. BZD ํ›„์—๋„ ์ง€์†๋˜๋ฉด levetiracetam 60 mg/kg IV, ์ตœ๋Œ€ 4,500 mg์„ 10โ€“15๋ถ„ infusionํ•œ๋‹ค.
  4. ๊ณ„์† ์ง€์†๋˜๋ฉด refractory status epilepticus pathway๋กœ intubation, anesthetic infusion, ICU ์น˜๋ฃŒ๋ฅผ ๊ณ ๋ คํ•œ๋‹ค.

์ถœ์ฒ˜

AES CSE guideline; ESETT NEJM 2019; DailyMed lorazepam injection; DailyMed levetiracetam injection.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.